Elysium Health study links NAD+ supplementation to menopause relief

The open-label study, published in Frontiers in Aging, tracked 40 women over the age of 35. Of these, 32 participants reported symptoms associated with the menopause transition, while eight reported minimal to no symptoms. After seven days of daily supplementation, those in the symptomatic group reported a 50% or greater reduction in the frequency and severity of issues including hot flashes, bloating, and sleep disturbances.

Beyond symptom relief, the research highlights a shift in the E2/E1 ratio, a key marker of estrogen balance. Marie Migaud, a study co-author and professor at The University of Western Australia, noted that the team hypothesized NAD+ support might influence this balance, a theory supported by the observed biochemical changes. The study also identified a previously unreported NAD+ metabolite, which researchers believe provides a clearer picture of how the body processes these precursors. To further its focus on reproductive longevity, Elysium Health has appointed Dr. Yousin Suh of Columbia University to its Scientific Advisory Board. The company intends to follow these preliminary results with a larger, randomized, placebo-controlled trial to validate the clinical potential of NAD+ modulation in women's health.